Puma Biotech’s Nerlynx remains a dud. Will a breast cancer expansion turn things around?

Sales of Puma Biotech’s only commercial product—breast cancer drug Nerlynx—still need improvement, company chief Alan Auerbach acknowledged. But as one analyst sees it, a label expansion may not even be enough to save the struggling med amid increased competition.